$82.4 Million is the total value of CAXTON CORP's 25 reported holdings in Q4 2018. The portfolio turnover from Q3 2018 to Q4 2018 was 45.5% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| SBBP | Buy | STRONGBRIDGE BIOPHARMA PLC | $29,586,000 | -3.1% | 6,604,065 | +4.9% | 35.89% | +27.2% |
| Buy | GARRISON CAP INC | $7,830,000 | -15.0% | 1,217,722 | +9.5% | 9.50% | +11.5% | |
| KALA | Buy | KALA PHARMACEUTICALS INC | $6,639,000 | +1212.1% | 1,357,639 | +2548.6% | 8.05% | +1620.9% |
| MTEM | Buy | MOLECULAR TEMPLATES INC | $6,562,000 | -23.9% | 1,624,241 | +1.6% | 7.96% | -0.1% |
| CMFN | Buy | CM FIN INC | $6,427,000 | -16.5% | 1,028,355 | +14.9% | 7.80% | +9.6% |
| SPY | New | SPDR S&P 500 ETF TRtr unit | $3,501,000 | – | 14,010 | +100.0% | 4.25% | – |
| ABDC | Buy | ALCENTRA CAP CORP | $487,000 | +41.2% | 75,303 | +30.6% | 0.59% | +85.3% |
| ACRS | Buy | ACLARIS THERAPEUTICS INC | $453,000 | -21.5% | 61,264 | +54.1% | 0.55% | +3.2% |
| EIGR | Buy | EIGER BIOPHARMACEUTICALS INC | $444,000 | +45.1% | 43,709 | +71.4% | 0.54% | +90.5% |
| FSK | New | FS KKR CAPITAL CORP | $421,000 | – | 81,348 | +100.0% | 0.51% | – |
| ARQL | Buy | ARQULE INC | $345,000 | -32.5% | 124,435 | +37.9% | 0.42% | -11.2% |
| MRKR | New | MARKER THERAPEUTICS INC | $296,000 | – | 53,329 | +100.0% | 0.36% | – |
| ARCC | New | ARES CAP CORP | $273,000 | – | 17,553 | +100.0% | 0.33% | – |
| FPAC | New | FAR PT ACQUISITION CORP | $262,000 | – | 27,116 | +100.0% | 0.32% | – |
| SBPH | Buy | SPRING BK PHARMACEUTICALS IN | $219,000 | -13.4% | 21,034 | +0.2% | 0.27% | +13.7% |
| MRNS | Buy | MARINUS PHARMACEUTICALS INC | $176,000 | -12.9% | 61,443 | +204.5% | 0.21% | +14.4% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| MOLECULAR TEMPLATES INC | 24 | Q2 2023 | 30.7% |
| STRONGBRIDGE BIOPHARMA PLC | 22 | Q3 2021 | 73.1% |
| GARRISON CAP INC | 18 | Q3 2020 | 9.9% |
| BERKSHIRE HATHAWAY INC DEL | 17 | Q3 2019 | 5.8% |
| EIGER BIOPHARMACEUTICALS INC | 17 | Q3 2022 | 1.7% |
| AGILE THERAPEUTICS INC | 16 | Q1 2018 | 55.5% |
| KALA PHARNACEUTICALS INC | 16 | Q4 2021 | 17.6% |
| CM FIN INC | 16 | Q1 2019 | 7.8% |
| SYNTA PHARMACEUTICALS CORP | 15 | Q2 2016 | 99.9% |
| CTI BIOPHARMA CORP | 14 | Q4 2021 | 8.7% |
View CAXTON CORP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Addex Therapeutics Ltd. | February 14, 2023 | 718,849 | 0.9% |
| Cardiff Oncology, Inc. | February 14, 2023 | 983,607 | 2.2% |
| Rezolute, Inc. | February 14, 2023 | 1,860,518 | 5.0% |
| Xeris Biopharma Holdings, Inc. | February 14, 2023 | 5,973,324 | 4.4% |
| CTI BIOPHARMA CORP | February 14, 2022 | 2,239,300 | 2.3% |
| Sierra Oncology, Inc. | February 14, 2022 | 1,119,322 | 7.0% |
| Strongbridge Biopharma plcSold out | January 05, 2022 | 0 | 0.0% |
| SUNESIS PHARMACEUTICALS INCSold out | February 16, 2021 | 0 | 0.0% |
| Alcentra Capital Corp | February 14, 2020 | 1,005,000 | 7.8% |
| Garrison Capital Inc. | February 14, 2020 | 1,223,096 | 7.6% |
View CAXTON CORP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
View CAXTON CORP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.